Long-term clinical remission maintained after cessation of zidovudine and interferon-α therapy in chronic adult T-cell leukemia/lymphoma
| Autor: | Claire Greiller, Charles R. M. Bangham, Anat Melamed, Nicolas Gillet, Aileen G. Rowan, Lucy Cook, Graham P. Taylor, Maria A Demontis, Aviva Witkover, Sophie Sagawe |
|---|---|
| Přispěvatelé: | Bloodwise |
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male 0301 basic medicine Oncology medicine.medical_specialty Neoplasm Residual Time Factors medicine.medical_treatment Immunology 1102 Cardiovascular Medicine And Haematology Antiviral Agents 03 medical and health sciences Zidovudine immune system diseases Internal medicine medicine Humans Leukemia-Lymphoma Adult T-Cell Zidovudine/interferon-α Bone Marrow Transplantation Human T-lymphotropic virus 1 Chemotherapy Hematology business.industry Remission Induction Interferon-alpha Chronic ATL HTLV Allografts medicine.disease Combined Modality Therapy Minimal residual disease Lymphoma Clinical trial Leukemia 030104 developmental biology Chronic Disease Drug Therapy Combination business Chronic Adult T-Cell Leukemia/Lymphoma medicine.drug |
| Zdroj: | International Journal of Hematology. 107:378-382 |
| ISSN: | 1865-3774 0925-5710 |
| DOI: | 10.1007/s12185-017-2361-7 |
| Popis: | © 2017 The Japanese Society of Hematology Globally, > 5–10 million people are estimated to be infected with Human T-lymphotropic virus type 1 (HTLV-1), of whom ~ 5% develop adult T-cell leukemia/lymphoma (ATL). Despite advances in chemotherapy, overall survival (OS) has not improved in the 35 years since HTLV-1 was first described. In Europe/USA, combination treatment with zidovudine and interferon-α (ZDV/IFN-α) has substantially changed the management of patients with the leukemic subtypes of ATL (acute or unfavorable chronic ATL) and is under clinical trial evaluation in Japan. However, there is only a single published report of long-term clinical remission on discontinuing ZDV/IFN-α therapy and the optimal duration of treatment is unknown. Anecdotal cases where therapy is discontinued due to side effects or compliance have been associated with rapid disease relapse, and it has been widely accepted that the majority of patients will require life-long therapy. The development of molecular methods to quantify minimal residual disease is essential to potentially guide therapy for individual patients. Here, for the first time, we report molecular evidence that supports long-term clinical remission in a patient who was previously treated with ZDV/IFN-α for 5 years, and who has now been off all therapy for over 6 years. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink